Your telemedicine provider can prescribe Emergency Use Authorized medications, standard prescription medications, and can also make recommendations for scientifically backed vitamins and supplements where appropriate.
Paxlovid (nirmatrelvir tablets; ritonavir tablets) is included in the Test-to-Treat program and are available through emergency use authorization (EUA) from the Food and Drug Administration (FDA). Here is the information about the Paxlovid EUA and the Fact Sheet for Patients.
Additional information on Paxlovid:
Paxlovid has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARSCoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death. The emergency use of Paxlovid is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization revoked sooner.